Deep learning for Alzheimer's disease: Mapping large-scale histological tau protein for neuroimaging biomarker validation.

Abnormal tau inclusions are hallmarks of Alzheimer's disease and predictors of clinical decline. Several tau PET tracers are available for neurodegenerative disease research, opening avenues for molecular diagnosis in vivo. However, few have been approved for clinical use.